YazanMadanatMD

PubMed

• Final phase I substudy results of ivosidenib in patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
  Courtney D DiNardo, Gail J Roboz, Justin M Watts, Yazan F Madanat, Gabrielle T Prince, Praneeth Baratam, Stéphane de Botton, Anthony S Stein, James M Foran, Martha L A...> ;Blood Advances. 2024 Apr 19
• CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) ...
  Yazan Madanat, Michael R Savona, Mikkael A Sekeres, Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Maria Diez-Campelo, David Valcárcel, Tymara Berry, Souria Doughert...> ;Journal of the National Comprehensive Cancer Network. 2024 Apr 5
• Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.
  Fazal, S., Naveen Pemmaraju, Yazan F Madanat, David Rizzieri, Salman Fazal, Raajit Rampal, Gabriel Mannis, Eunice S Wang, James Foran, Andrew A Lane> ;Leukemia & Lymphoma. 2024 May 1
• Author Correction: Molecular patterns identify distinct subclasses of myeloid neoplasia.
  Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Laila Terkawi, Hussein Awada, Olisaemeka D Ogbue, Ramsha Ahmed, Simona Pagliuca, Hassan Awada, Yasuo Kubota, Mi...> ;Nature Communications. 2024 Feb 8
• Genomic heterogeneity within B/T mixed phenotype acute leukemia in a context of an immunophenotype.
  Koduru, P., Collins, R., Chung, S., Zheng, R., Fuda, F., Gagan, J., Weinberg, O., Cantu, M., Ludwig, K., Truscott, J., Madanat, Y., Chen, W.> ;Leukemia Research Reports. 2024 Jan 1
• A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or ...
  Jan Philipp Bewersdorf, Rory M Shallis, Elad Sharon, Silvia Park, Rahul Ramaswamy, Caroline E Roe, Jonathan M Irish, Anne Caldwell, Wei Wei, Abdulraheem Yacoub, Yazan ...> ;Annals of Hematology. 2024 Jan 1
• 4 citations
  Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, ra...
  Platzbecker, U., Santini, V., Fenaux, P., Sekeres, M., Savona, M., Madanat, Y., Díez-Campelo, M., Valcárcel, D., Illmer, T., Jonášová, A., Bělohlávková, P., Sherman, L...> ;Lancet. 2024 Jan 20
• Treatment Considerations of Myelodysplastic Syndromes/Neoplasms for Pathologists.
  Yazan F Madanat, Amer M Zeidan> ;Clinics in Laboratory Medicine. 2023 Dec 1
• Evaluation of a decentralized investigational drug service pharmacist in a cancer clinical trial infusion unit.
  Christina Baroody, Melissa Sandler, Christine Hong, Yazan F Madanat, Stefanie Conley> ;Journal of Oncology Pharmacy Practice. 2023 Oct 17
• Updates on risk stratification and management of lower-risk myelodysplastic syndromes/neoplasms.
  Talha Badar, Yazan F Madanat, Amer M Zeidan> ;Future Oncology. 2023 Sep 1
• Identifying patients at risk for hereditary myeloid malignancy syndromes incorporating a novel, self-administered questionnaire to an initial screening platform.
  Mohammad Faizan Zahid, Kelsey Moriarty, Courtney Dryden, Olga Weinberg, Misha Asif, Ruth Ikpefan, Julia M Anderson, Robert H Collins, Stephen S Chung, Weina Chen, Prap...> ;European Journal of Haematology. 2023 Dec 1
• 1 citations
  Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia.
  Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz, Ben Ponvilawan, Ishani Pandit, Yasuo Kubota, Olisaemeka D Ogbue, Misam Zawit, Yazan Madanat, Taha Bat, Suresh K...> ;Journal of Hematology & Oncology. 2023 Aug 3
• Presence but not number of secondary type mutations influences outcome in de novo AML without MDS-associated or recurring cytogenetic abnormalities.
  Olga K Weinberg, Miguel D Cantu, Jeffrey Gagan, Yazan F Madanat, Daniel A Arber, Robert P Hasserjian> ;Ejhaem. 2023 Aug 1
• Anti-Spike Antibody Responses in Allogeneic Stem Cell Transplant Recipients to Two Doses of COVID-19 mRNA Vaccination: A Retrospective, Single-Center Analysis.
  Jaime L Shahan, Robert H Collins, Prapti Patel, Yazan F Madanat, Madhuri Vusirikala> ;Journal of the Advanced Practitioner in Oncology. 2023 Jul 1
• 2 citations
  Paradigm Shift in the Management of Acute Myeloid Leukemia-Approved Options in 2023.
  Naveen Premnath, Yazan F Madanat> ;Cancers. 2023 May 31
• 2 citations
  Molecular patterns identify distinct subclasses of myeloid neoplasia.
  Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Laila Terkawi, Hussein Awada, Olisaemeka D Ogbue, Ramsha Ahmed, Simona Pagliuca, Hassan Awada, Yasuo Kubota, Mi...> ;Nature Communications. 2023 May 30
• 1 citations
  Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia.
  Naveen Premnath, Yazan F Madanat> ;Cancers. 2023 May 29
• 2 citations
  Real-world outcomes of frontline venetoclax-based therapy in older adults with acute myeloid leukemia: an analysis utilizing EHR data.
  Fieke W Hoff, Prapti A Patel, Andrew J Belli, Eric Hansen, Heidi Foss, Molly Schulte, Ching-Kun Wang, Yazan F Madanat> ;Leukemia & Lymphoma. 2023 Jun 1
• Post-transplant cyclophosphamide and early mixed donor Chimerism in myeloid malignancies; a single-center experience.
  Fieke W Hoff, Stephen S Chung, Prapti A Patel, Naveen Premnath, Jude Khatib, Mirjana Tadic-Ovcina, Abeer AhmedRabie, Debra Helton, Selamawit Yohannes, Jaime Shahan, He...> ;Transplant Immunology. 2023 Apr 1
• 2 citations
  Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid Neoplasia.
  Waled Bahaj, Tariq Kewan, Carmelo Gurnari, Arda Durmaz, Ben Ponvilawan, Ishani Pandit, Yasuo Kubota, Olisaemeka D Ogbue, Misam Zawit, Yazan Madanat, Taha Bat, Suresh K...> ;Research Square. 2023 Mar 9
• 2 citations
  Molecular Drivers of Myelodysplastic Neoplasms (MDS)-Classification and Prognostic Relevance.
  Fieke W Hoff, Yazan F Madanat> ;Cells. 2023 Feb 15
• 12 citations
  North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
  Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matth...> ;Blood. 2023 Feb 9
• 3 citations
  Clinical and molecular characteristics associated with Vitamin C deficiency in myeloid malignancies; real world data from a prospective cohort.
  Naveen Premnath, Stephen S Chung, Olga K Weinberg, Ruth Ikpefan, Mohak Pandey, Gurbakhash Kaur, Praveen Ramakrishnan Geethakumari, Aimaz Afrough, Farrukh T Awan, Larry...> ;Leukemia Research. 2023 Feb 1
• 3 citations
  Advances in myelodysplastic syndromes: promising novel agents and combination strategies.
  Yazan F Madanat, Zhuoer Xie, Amer M Zeidan> ;Expert Review of Hematology. 2023 Jan 1
• 4 citations
  Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.
  Junhua Lyu, Yuxuan Liu, Lihu Gong, Mingyi Chen, Yazan F Madanat, Yuannyu Zhang, Feng Cai, Zhimin Gu, Hui Cao, Pranita Kaphle, Yoon Jung Kim, Fatma N Kalkan, Helen Step...> ;Cancer Discovery. 2023 Jan 9
• Join now to see all

Abstracts/Posters

• Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
  Yazan F. Madanat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018